CRBU (Caribou Biosciences) LT-Debt-to-Total-Asset: 0.17 (As of Mar. 2026)

What is Caribou Biosciences LT-Debt-to-Total-Asset?

Caribou Biosciences CRBU -0.77% 64 LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus rates CRBU with a GF Score™ of 64/100 and a GF Value™ of $1.68 (Modestly Overvalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Caribou Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.17.

Caribou Biosciences's long-term debt to total assets ratio increased from Mar. 2025 (0.09) to Mar. 2026 (0.17). It may suggest that Caribou Biosciences is progressively becoming more dependent on debt to grow their business.

Caribou Biosciences (NAS:CRBU) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Caribou Biosciences LT-Debt-to-Total-Asset Related Terms

Caribou Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences LT-Debt-to-Total-Asset Chart

Caribou Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.07

0.06

0.08

0.15

Caribou Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.11	0.12	0.15	0.17

64GF Score

Caribou Biosciences Inc CRBU

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Caribou Biosciences LT-Debt-to-Total-Asset Calculation

Caribou Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	26.026	/	175.367
	=	0.15

Caribou Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	25.659	/	148.998
	=	0.17

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.17 mean?

Caribou Biosciences (CRBU) has a LT-Debt-to-Total-Asset of 0.17 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Caribou Biosciences and its competitors.

Is Caribou Biosciences' LT-Debt-to-Total-Asset too high?

Caribou Biosciences' current LT-Debt-to-Total-Asset is 0.17. Overall, Caribou Biosciences has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Caribou Biosciences' LT-Debt-to-Total-Asset compare to YDES and PRQR?

Caribou Biosciences' LT-Debt-to-Total-Asset of 0.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current LT-Debt-to-Total-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Caribou Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.68, compared to a current price of $1.93 — trading 14.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.17. Caribou Biosciences' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued. The current stock price of $1.93 is trading 14.6% above its estimated GF Value™ of $1.68. GuruFocus considers Caribou Biosciences to be Modestly Overvalued.

Key valuation signals for CRBU:

LT-Debt-to-Total-Asset: 0.17
GF Value™: $1.68 vs. price of $1.93 (14.6% above fair value)
GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies YDES PRQR CRBP ABOS NRXP PYXS TNYA MIST TLSA SPRB VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710

Website https://www.cariboubio.com

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

64GF Score

Get the complete analysis for CRBU

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93

Price

$1.68

GF Value

View CRBU Analysis

See LT-Debt-to-Total-Asset data for all stocks →